WO1997023605A1 - Thermostable proteolytic enzyme from thermoactinomyces thalpophilus thm1 - Google Patents

Thermostable proteolytic enzyme from thermoactinomyces thalpophilus thm1 Download PDF

Info

Publication number
WO1997023605A1
WO1997023605A1 PCT/GB1996/003192 GB9603192W WO9723605A1 WO 1997023605 A1 WO1997023605 A1 WO 1997023605A1 GB 9603192 W GB9603192 W GB 9603192W WO 9723605 A1 WO9723605 A1 WO 9723605A1
Authority
WO
WIPO (PCT)
Prior art keywords
enzyme
thml
protease
thalpophilus
activity
Prior art date
Application number
PCT/GB1996/003192
Other languages
French (fr)
Inventor
Jasen Kingsley Anderson
George Kenneth Grimble
Donald Arthur Cowan
Original Assignee
Helix Biotechnology Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9526375.2A external-priority patent/GB9526375D0/en
Priority claimed from GBGB9600521.0A external-priority patent/GB9600521D0/en
Application filed by Helix Biotechnology Ltd. filed Critical Helix Biotechnology Ltd.
Priority to AU12009/97A priority Critical patent/AU1200997A/en
Publication of WO1997023605A1 publication Critical patent/WO1997023605A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Definitions

  • This invention relates to micro-organisms capable of producing thermostable extracellular proteolytic enzymes. It also relates to the enzymes themselves, their preparation and use in the preparation of protein hydrolysates.
  • Proteins which have been partially digested by food-grade enzymes i.e. protein hydrolysates
  • the cells in the centre of the picture represent the absorptive cells lining the wall of the intestine.
  • Di- and tripeptides are absorbed intact (Craft et al . , Gut 9 425-437 (1968); Ferraris et al . , Am. J. Physiol . 257 G689-G697 (1989) ; Nicholson e ⁇ al . , Clin . Sci . Mol . Med . 54 205-207 (1978); Nicholson et al . , Eur. J. Clin . Inves t . 9 349-354 (1979) ; Silk Gut 15 494-501 (1974) ; and Silk e ⁇ al . , Br. J. Nutr.
  • the allergic patient Predigestion of proteins also reduces the allergic potential of the protein, and is thus of benefit to infants with hypersensitivity to milk proteins. Since the allergic potential of a hydrolysate decreases as the size of its constituent peptides also decreases, this type of di- and tripeptide-based protein hydrolysate can be applied to these patients.
  • cysteine and tyrosine have poor solubility, whilst glutamine has poor stability) , have led to considerable effort being put into soluble and stable synthetic dipeptides containing these problem amino acids.
  • a simpler approach would be to use protein hydrolysates containing di- and tripeptides as a much cheaper alternative to synthetic peptides, and even to free L-amino acids.
  • Dipeptides have half the osmolarity of the same solution weight of free amino acids. They are therefore less irritating to veins if infused intravenously.
  • intravenous nutrition solutions consist of a mixture of amino acids and glucose in a fat emulsion, together with minerals and vitamins. These solutions are hypertonic and are too irritant to infuse into a peripheral vein. They are therefore infused through a catheter which is surgically implanted under the collar bone and into a large central vein, enabling the high blood flow to dilute the solution (Peripheral Parenteral Nutrition -- PPN) . This technique has its risks and clinicians prefer infusing nutrient solutions into peripheral (e.g. arm) veins.
  • proteases are one of the half-dozen major industrial and food enzymes.
  • the proteases used for food use are fungal
  • ⁇ ucor proteases in cheese-making plant (e.g. papain), mammalian ⁇ e . g. pancreatic proteases) and to a lesser extent bacterial (e.g. Bacillus proteases) .
  • plant e.g. papain
  • mammalian ⁇ e . g. pancreatic proteases e.g. bacterial
  • Bacillus proteases e.g. Bacillus proteases
  • proteases and peptidases exhibit a wide-range of activities, especially in their ability to cleave at specific amino acid residues in the native protein. This gives the possibility of predicting the peptide products of protein hydrolysis. Since the nature of the final end- product is known (di- and tripeptides) , this can be achieved by careful choice of enzyme (s) .
  • THM1 a strain of Thermoactinomyces thalpophilu ⁇ designated THM1.
  • T ⁇ er ⁇ ioactinomyces thalpophilus THM1 has been designated as strain HB 2682 in the Applicant's internal collection of strains and deposited under the terms of the Budapest Treaty at the National Collection of Industrial and Marine Bacteria Limited (NCIMB) , Auris Business Centre, 23 St Macher Drive, Aberdeen AB2 1RY, on 18 December 1995 and given accession number NCIMB 40778. The deposit was found to be viable on 18 December 1995.
  • NCIMB National Collection of Industrial and Marine Bacteria Limited
  • T. thalpophilus is a species within the genus Thermoactinomyces , the only genus within the group Thermoactinomycetes. Thermoactinomyces spp. are gram positive bacteria which are aerobic and saprophytic chemo-organotrophs. Most members of the genus are, like T. thalpophilu ⁇ , thermophilic. Strains of T. thalpophilus have been isolated from soil, hay, cereal grain, sugar cane bagasse, cotton, grass compost, mushroom compost, peat, air conditioners and manure.
  • the invention encompasses T. thalpophilus THM1 and micro ⁇ organisms derived from it.
  • T. thalpophilus THM1 can be used in the derivation of other strains of micro- organisms by any of the usual methods of microbiology, including mutation (prepared for example by ultra violet light or other radiation or by chemical mutagenesis) , environmental selection, classical genetic transfer or recombinant DNA techniques.
  • the micro-organisms of the invention produce a thermostable proteolytic enzyme whose properties are singularly useful in the preparation of protein hydrolysates .
  • thermostable proteolytic enzyme which is producible by Thermoactinomyces thalpophilus THMl (NCIMB 40778) .
  • the heat stability of the enzyme allows hydrolysis reactions to be carried out at elevated temperatures, increasing reaction rates and reducing the danger of microbial contamination
  • the enzyme may be characterised that it:
  • (a) has a pH optimum of about 8;
  • (b) has a temperature optimum of about 70°C;
  • (c) is substantially inhibited by ImM phenylmethyl ⁇ sulphonylfluoride but substantially not inhibited by lOmM dimethylsulphoxide, dithio ⁇ threitol or ⁇ -mercaptoethanol ;
  • thermostable at least partially dependent on the presence of calcium for its thermostability; and (e) is thermostable at 50°C for at least 6 hours without substantial loss of activity.
  • Extracellular proteases from a number of thermophilic Actinomycetes strains have been identified, purified and partially characterised.
  • the characterisation of an alkaline protease from an alkalophilic Thermoactinomyces isolate (HS682) has been reported (Tsuchiya et al . , Biosc . Biotech . Biochem . 56(2) , 246-250 (1992)) .
  • This enzyme shows properties broadly similar to the specific enzyme disclosed herein (inhibition by PMSF, stabilisation by calcium) but has a significantly higher pH optimum (11.5-13.0) .
  • the HS682 source organism although not identified to species level, has very different physiological characteristics to the organism claimed herein, with a pH optimum for growth of 10.3 and a maximum growth temperature of 60°C (Tsuchiya et al . , Agric . Biol . Chem. 55(12) , 3125-3127 (1992)) .
  • a protease purified and partially characterised from an isolate assigned the taxonomy of Thermoactinomyces thalpophilus (Odibo & Obi, MIRCEN J. 4 327-332 (1988)) showed characteristics significantly different from the enzyme specifically described herein. Whereas the specific enzyme has been identified as a calcium- stabilised serine protease, the prior reported T. thalpophilus enzyme is said to be a neutral protease inhibited by heavy metals but not by the covalent serine reagent diisopropylfluoropnosphate.
  • thermostable serine protease isolated from Thermoactinomyces vulgaris has been studied in considerable detail (Leuchtenberger et al . , Z. Allgem. Mikrobiol . 19(1) 27-35 (1979) ; Fr ⁇ mmel & H ⁇ hne, Biochim . Biophys . Acta 670 25-31 (1981) ; Kretschmer et al . , Z. Allgem. Mikrobiol . 22 (10) 693-703 (1982) ; Behnke et al . , Z. Allgem. Mikrobiol . 22 (8) 511-519 (1982); Br ⁇ mme & Kleine Curr. Microbiol . 11, 93-100 (1984) .
  • Thermitase is substantially different from the enzyme specifically described herein, both on the basis of functional properties and because of the taxonomic difference of the source organism.
  • thermostable serine protease derived from the thermophilic Actinomycete Thermoactinomyces thalpophilu ⁇
  • thermophilic Actinomycete Thermoactinomyces thalpophilu ⁇ a thermostable serine protease derived from the thermophilic Actinomycete Thermoactinomyces thalpophilu ⁇
  • the invention therefore provides in a third aspect a serine protease derivable from T. thalpophilus .
  • An enzyme of the invention may be produced by culturing a micro-organism as described above under conditions which cause expression (and preferably secretion) of the enzyme; suitable conditions include the use of a growth medium including glutamate.
  • the enzyme may be harvested from the culture medium.
  • Enzymes of the invention may be substantially pure preparations, as determined for example by iso-electric focusing, SDS-PAGE, sequencing or crystallisation, for example. Alternatively, they may be impure preparations or crude extracts, such as ammonium sulphate precipitations or partially purified fractions (eg gel filtration or chromatography fractions. The purity of the enzyme preparation will ultimately depend on its intended use.
  • the enzyme may be covalently or non-covalently immobilised onto an appropriate immobilisation matrix.
  • the enzyme may be modified in its amino acid sequence (either chemically or by site-directed mutagenesis) ; but enzymes within the scope of the invention will generally be substantially (ie at least 60, 70, 80, 90, 95 or even 99%, in increasing order of preference) homologous to the prototype enzyme. Fusion proteins including an enzyme of the invention are also contemplated.
  • the enzymes of the invention are useful in the preparation of protein hydrolysates.
  • a method of preparing a protein hydrolysate comprising digesting one or more proteins with an enzyme as described above.
  • the digestion may be carried out substantially to completion, in which case the product will contain a high proportion of low molecular weight peptides (particularly di- and tri-peptides) or it may be terminated before completion, in which case it will contain a lower proportion of low molecular weight peptides and a higher proportion of high molecular weight peptides. Longer hydrolysis products are preferred for the production of pharmaceutical and/or nutritional products.
  • the product will, in relation to the starting material (s) be enriched in di- and tripeptides and virtually free of single amino acids.
  • milk proteins may be used, particularly lactalbumin, such as bovine lactalbumin. More or less pure bovine lactalbumin preparations may be used; other proteins useful as substrates include other milk proteins (such as caseins) and plant proteins (such as soy proteins) .
  • Substrate proteins may be pure or impure preparations (containing, for example, lipidaceous material) and may be in a native or denatured state.
  • the reaction volume may be any volume which is convenient or desirable.
  • the reaction time depends on the substrate, the temperature, other reaction conditions and the desired end point but will typically be from 30 minutes to 48 hours.
  • the reaction temperature will typically be from 20°C to 100°C and is preferably from 45°C to 80°C.
  • the enzyme concentration may be from 0.1 to 1000 units/ml, preferably from 5 to 50 units/ml; and the substrate concentration may be from 0.1% to 80% (w/v) , preferably from 1 to 20%.
  • the invention also relates to a protein hydrolysate preparable by the above method, as well as to food and/or pnarmaceutical preparations comprising such a hydrolysate.
  • Other envisaged uses include cosmetic and diagnostic uses and the use of protein hydrolysates as agents for modifying texture or surface coating. Fields of use are within the molecular biological, medical and pharmacological research, medical diagnostics and therapy, and the pharmaceutical, biotechnological, chemical and food industries.
  • protein hydrolysates are incorporated in many food, dietary and cosmetic preparations for the purposes of enhancing physical, organoleptic and nutritional qualities.
  • protein hydrolysates may be used to prepare for use microtitre plates or blotting membranes.
  • Protein hydrolysates have potential application in medical diagnostics as targets for drug screening or in receptor ligand binding.
  • protein hydrolysates may be used for multiple purposes including the modification of the physical properties of emulsions such as paints, incorporation in polymeric substances and coatings for modern materials.
  • a micro-organism was isolated from a dry soil sample collected from a dry bed of a thermal stream at the Taupo thermal area in New Zealand.
  • the micro-organism grows optimally at 50-55 * C and shows proteolytic activity in casein agar plates.
  • the micro-organism was identified as a strain of Thermoactinomyces thalpophilus by morphological and physiological characterisation.
  • the novel strain is induced to produce extracellular protease by growth in a nutrient medium containing Na-glutamate.
  • the extracellular proteolytic activity is enriched by fractionated ammonium-sulphate precipitation. Most of the activity is found in the 50-80% (NH 4 ) 2 S0 4 fraction.
  • This fraction gives after dialysis and ultrafiltration an enzyme preparation of about 3000u/ml as assayed with azocasein as substrate.
  • the enzyme is most active at a pH of 8.0 and at a temperature of 70 * C.
  • the enzyme belongs to the family of serine proteases as shown by its 98.4% inhibition by phenylmethylsulphonylfluoride (PMSF) at 1 mM.
  • PMSF phenylmethylsulphonylfluoride
  • Ethylenediaminotetraacetic acid does not inhibit the enzymatic activity of the novel proteolytic enzyme but destabilises the enzyme, thereby reducing its thermal stability. It may be that calcium ions are necessary to stabilise the folding of the protein for its activity at high temperatures and possibly protecting against autolysis .
  • the enzyme finds particular application in the hydrolysis cf the milk proteins, at alkaline pH, for the production of hydrolysates enriched in di- and tripeptides.
  • FIGURE 1 which has already been referred to, schematically illustrates pathways of amino acid absorption in the human intestine
  • FIGURE 2 refers to Example 10.2 and shows the effect of pH on THMl protease
  • FIGURE 3 refers to Example 10.3 and shows the temperature optimum of THMl protease
  • FIGURE 4 refers to Example 10.6 and shows the effect of calcium on THMl protease
  • FIGURE 5 refers to Example 10.7 and shows the effect of temperature on the thermostability of THMl protease.
  • Example 1 Isolation of the micro-organism A dry soil sample from a dry bed of a thermal stream at the Taupo thermal area in New Zealand was resuspended in sterile distilled water. Approximately 50 ⁇ l of the suspended sample was spread on a Nutrient Agar plate and incubated at 55 * C overnight. After incubation a large white colony was picked from this plate and screened for protease production.
  • Example 2 Screen for extracellular proteolytic activity
  • the isolated micro-organism from Example 1 was subsequently tested for extracellular protease activity by culturing on a casein agar plate consisting of casein 2%, tryptone 0.5%, yeast extract 0.3%, agar 15%, pH 7.2, at 55'C overnight.
  • the isolated organism produces extracellular protease activity as shown by zones of casein denaturation and progressive clearing by proteolytic activity.
  • Example 3 Characterisation of the micro-organism
  • NCIMB National Collection of Industrial and Marine Bacteria
  • THMl grows with white aerial mycelium at 50oC on CYC agar. On this agar the organism shows a slightly dark pigmented substrate mycelium and produces a white aerial mycelium in 24 hrs. THMl is able to grow on CYC agar containing tyrosine 5 mg/ml and novobiocin 25 ⁇ g/ml. Melanin was produced after 2-3 days.
  • the ability to grow on CYC agar containing novobiocin at 50oc is characteristic of rherm ⁇ actinomycetes species and the production of melanin on CYC agar containing tyrosine is characteristic of Thermoactinomyces thalpophilus and rher ⁇ ioactino-Tjyces putidus.
  • THMl was able to grow on CYC agar in the presence of 200 mM NaCl. On agar containing Nutrient broth No. 2 powder
  • THMl is Arbutin and Esculin minus.
  • THMl is a strain of Thermoactinomyces thalpophilus (T. Cross, 'The monosporic Actinomycetes' pp 2091-2102 in 'The Prokaryotes' ) .
  • Two oligonucleotide primers were designed by reverse translation of conserved regions of serine proteases, particularly thermitase (Meloun et al . , FEBS Lett . 183 195-200 (1985)) and the Thermoactinomyces species protease published by Lee et al . , Biosci . Biotechnol . Biochem. 60 840-6 (1996) , using the codon usage bias of Thermoaci ⁇ oinycetes.
  • the first region chosen spans amino acid positions 14 to 21 in the thermitase sequence (S ISS-PROT P04072) and 154 to 161 in the Thermoactinomyces protease sequence published by Lee et al . (EMBL U31759) , respectively.
  • the second region covers the serine protease active site, amino acid positions 225 to 232 in the thermitase sequence and 367 to 374 in the Thermoactinomyces protease sequence published by Lee et al . , respectively.
  • Primers having the sequences 5' -GGA CCG CAA AAA GTC CAA GCT CCC-3' (SEQ ID NO:l) and 5' -CCT GCC ACA TGC GGT GTG GCC AT-3' (SEQ ID NO:2) were synthesised.
  • the two oligonucleotides were used for PCR amplification of a DNA fragment (predicted length of 662 bp) , using genomic DNA from the different Thalpophilus strains obtained from the National Collection of Industrial and Marine Bacteria (NCIMB) and THMl as template.
  • NCIMB National Collection of Industrial and Marine Bacteria
  • THMl As a positive control DNA from T. vulgaris, also obtained from the NCIMB collection (NCIMB 11364) was used.
  • the genomic DNAs were isolated according to standard procedures (Sambrook et al . Molecular Cloning, 2nd ed., Cold Spring Harbor Laboratory Press (1989)) . PCR amplification of the DNA samples yielded a band of the expected size only with T. vulgaris DNA as a template. The negative result indicates that the THMl protease is different from thermitase at the genomic level .
  • Strain THMl was grown in 50mL of CYC medium overnight at 50°C. The culture was concentrated 10-fold by centrifugation (5 minutes at 1000 rpm) and resuspended in CYC medium. 500 ⁇ L of the suspension was added to a sterile lyophilisation tube and dried overnight under vacuum. The lyophilisation tube was sealed under vacuum and forwarded, at room temperature, to NCIMB, by whom it was received on 18 December 1995 and allocated deposit number NCIMB 40778.
  • Example 6 Isolation of proteolytic activity The partial enrichment of the proteolytic enzyme was performed using ammonium sulphate precipitation. A fresh culture of the microorganism was grown on a Nutrient Agar plate overnight at 50"C. A single colony was picked and inoculated into 50 mL of sterile Nutrient broth. The culture was incubated with shaking at 300rpm overnight at 50 * C. To 1000 mL of protease enrichment broth containing sodium glutamate 1.5%, KH 2 P0 4 0.045%, tryptone 0.2%, yeast extract 0.05%, and CaCl 2 0.147%, pH 7.0, 1 mL of the overnight culture was added and the culture incubated for 24 hours at 50'C with shaking at 200rpm.
  • the liquid was centrifuged as before and the pellet retained.
  • the second pellet was resuspended in 15 mL 0.1 M Tris buffer, lOmM CaCl 2 pH 8.0.
  • the resuspended pellet was placed in an Amicon Centricon 10 ultrafiltration unit and centrifuged at 2500xg for 45 min.
  • the protein solution was desalted 4 times by repeated addition of buffer to 15mL and centrifugation as above with a subsequent concentration of the solution down to a total of 3mL.
  • the proteolytic activity of the protein isolate was assayed as described in Example 10.1 using 100 ⁇ l of a 1/200 dilution of the preparation.
  • the optimized broth (PPB) has the following composition per litre medium:
  • a 15 L fermentation of Thermoactinomyces thalpophilus THMl was performed in a fermenter of nominal volume of 16 L over 46 hours and the extracellular protease activity determined as described in Example 6.1.
  • the cells were harvested by filtration and the culture broth filtered over a 10 kDa ultrafiltration membrane
  • the protease was purified on Phenyl-Sepharose using a double gradient elution system.
  • THMl protease (6000 U/ml, specific activity 5.5 U/ ⁇ g) was applied at a flow rate of 2 ml/min to a 20 ml Phenyl-Sepharose column, pre-equilibrated with Tris-Cl 50mM, CaCl 2 20mM, pH 8.0 (buffer A) .
  • the column was washed with 5 volumes of buffer A, and a gradient of 1-100% of buffer B (Tris'Cl 50mM, CaCl 2 20mM, NaCl IM, pH 8.0) over 5 column volumes.
  • the enzyme was eluted with a second gradient using buffer B and buffer C (Tris-Cl 50mM, CaCl 2 20mM, NaCl IM, acetone 20%) .
  • the eluate was fractionated and the fractions tested for activity as described in Example 6.1 Out of 12000 units applied to the column, a total of 7500 units were recovered. The final yield was 62.5 % of initial activity loaded.
  • the specific activity of the activity recovered was measured as 12 U/ ⁇ g protein, a 2.2-fold purification.
  • Example 10 Characterisation of the proteolytic enzyme.
  • the parameters examined of the enzyme isolated were pH and temperature optimums, thermostability, protease type by inhibition and isoelectric point.
  • the pH optimum of the enzyme preparation was examined using azocasein 0.2% as substrate dissolved in a multi-pH buffering solution consisting of 50mM Na 2 HP0 4 , 50mM H 3 B0 4 , 50mM CH 3 COOH, adjusted to the pH values of 5, 6, 7 ,8, 9 10 and 11 with 5M NaOH. Aliquots of 900 ⁇ l of the buffered azocasein were preincubated at 70"C in duplicate microcentrifuge tubes. A lOO ⁇ l aliquot of 1/200 diluted concentrated THMl enzyme preparation was added to initiate each reaction. The assay then proceeded as previously described. The results are shown in Figure 2.
  • the inhibition of the partially purified protease was examined using the serine protease inhibitor, phenylmethylsulphonylfluoride (PMSF) and the thiol compounds, dimethylsulphoxide (DMSO) , dithiolthreitol (DTT) and ⁇ -mercaptoethanol.
  • PMSF phenylmethylsulphonylfluoride
  • DMSO dimethylsulphoxide
  • DTT dithiolthreitol
  • ⁇ -mercaptoethanol A lO ⁇ l aliquot of 1/10 dilution of the THMl enzyme preparation was incubated with the desired concentration of inhibitory reagent in tris buffer 0.IM pH 8.0 to a total of lOO ⁇ l ac room temperature for 30 minutes. After incubation the azocasein assay was performed, as described before, using the lOO ⁇ l reaction volume. The change in absorbance at 420nm was determined and compared to an enzyme only control. See Table 4. Table 4. Effect of In
  • the molecular mass of the protease of THMl was analysed on a 15% SDS-PAG.
  • a sample containing 5 ⁇ g of purified THMl protease (Example D) was incubated either in the presence of 40 mM PMSF or ⁇ 0 mM EDTA for 30 min. at room temperature.
  • SDS-sample buffer was added and the samples boiled for 2 minutes .
  • the samples were loaded onto the gel and electrophoresed at 25mA for 2.5 hours. Staining with Coomassie Brilliant Blue showed a single band in the sample incubated in the presence of PMSF (lane 1) and in addition a smaller degradation product in the sample incubated in the presence of EDTA.
  • the major band shows a molecular mass of about 32 kDa as determined from comparison with marker proteins.
  • THMl protease preparation was prepared in Tris lOOmM pH 8.0 to final volumes of 500 ⁇ l which were incubated at 50, 60, 70 and 80"C. Aliquots of lO ⁇ l were taken at the beginning of the incubation and then hourly for 6 hours. The samples were assayed using the azocasein 0.2% protease assay at 70 * C method as stated in Example 10.1. The initial activity of each was determined to be 100% and the residual activity calculated. Results are shown in Figure 5.
  • the isoelectric point of the enzyme was determined using the Pharmacia PHASTSYSTEM TM Electrophoresis unit . Two
  • PhastGel isoelectrophoresis gels pH 3-9, were set up according to the Pharmacia PhastSystem manual and loaded identically with l ⁇ l of protease preparation and electrophoresed according to the IEF program. After electrophoresis, one gel was stained with coomassie blue using the Pharmacia protocol and the second gel was checked for activity by incubating with 10 ml Casein 2%, Tris lOOmM pH 8.0 for 30 minutes at 50"C. The resultant activity detected on the gel incubated with casein substrate aligned with a band detected on the coomassie blue stained gel which was located in comparison to standards at a pi of above 8.
  • a SUPE OSE 12 HR 10/30 size exclusion column was equilibrated with buffer A (50 mM Tris-Cl, pH 7.5, 100 mM KCl) .
  • the column was calibrated with dextran blue (Sigma D4772, 1 mg/ml) and protein standards (cytochrome C, Sigma C7150, 2 mg/ml; carbonic anhydrase, Sigma C7025, 2 mg/ml; apoprotinin, Sigma A3886, 3 mg/ml; albumin, Sigma A8531, 5 mg/ml) in 200 ⁇ l buffer B (50 mM Tris-Cl, 100 mM KCl, 5% v/v glycerol) at 0.1 ml/min.
  • THM-1 protease 200 ⁇ l THM-1 protease (1.025 mg/ml; 3.4 U/ ⁇ g) in buffer B were applied to the column and eluted with buffer A at 0.1 ml/min. Twenty 0.25 ml fractions were collected and activity determined as described. No activity was detectable in fractions 1 to 12; the total applied activity was recovered in fractions 13 - 17, indicating an apparent molecular mass of 8 kDa as determined from the elution profile of the marker proteins. The active fractions were pooled, freeze dried and the protease resuspended in 250 ⁇ l Tris'Cl, pH 6.8, yielding a protein concentration of 430 ⁇ g/ml.
  • Example 11 Proteolytic digestion of Bovine Lactalbumin by THMl Protease.
  • a 5% suspension of insoluble, denatured bovine lactalbumin substrate was prepared in K 2 HP0 4 0.1M, pH 10 CaCl 2 5mM with penicillm-G 20 ⁇ g/ml to suppress bacterial contamination.
  • a 20ml volume of substrate was incubated with 20un ⁇ ts/ml of THMl protease at 50'C with gentle shaking in a 50ml conical flask for a total of 24 hours. Aliquots of 1ml were taken at various time points. The pH of the reaction mixture was continually checked and read usted to pH 10 using IM NaOH if required.
  • the digestion reaction was performed identically as stated aoove except that the pH was modified to pH 9.5.
  • the products of the reaction were analysed as described Example 12. The results shown in Table 5.
  • Example 12 Analysis of Protein substrate digestions via Cu 11 -Sephadex column chromatography and total acid hydrolysis/OPA-MESNA assay.
  • a CU I : -SEPHADEX column was prepared as follows. 80 mL of copper sulphate 0.08 M was added to 21.3g SEPHADEX fine G- 25, and left overnight at room temperature. 40 mL NaOH IM was added with vigorous stirring to initiate the formation of a copper complex with the SEPHADEX. The suspension was centrifuged, the supernatant and any copper hydroxide layer removed and a further 40ml of NaOH IM was added. The SEPHADEX complex was recentrifuged then washed twice with Na 2 B 4 0 7 buffer 50 mM, pH 11.5 and centrifuged.
  • the pellet was then resuspended with about 20-50mL of the borate buffer and two columns were poured, a 40cm column and a 5 cm precolumn. The columns were put in place at 4 * C and equilibrated using the said borate buffer, degassed with 100% helium, with a lml/min flow rate monitored at a 280 nm wavelength. Proteolytic digestion samples of 0.5 mL were loaded and fractions were collected for further analysis. A corresponding molecular size profile was plotted from detection of elution products to which three molecular size categories were assigned. See Table 5. 12.2 Total acid hydrolysis of chromatographic fractions.
  • o-phthaldialdehyde (OPA) 40mM (lOx concentration) in methanol and 2-mercaptoethanesulphonic acid (MESNA) in Na 2 B 4 0 7 buffer lOOmM pH 10.5 (lx concentration) were prepared.
  • An appropriate volume of sample from either the before or after total acid hydrolysis samples was added and adjusted to a final volume of 400 ⁇ l with borate buffer 50mM pH 10.5.
  • 200 ⁇ l of MESNA was added followed by 200 ⁇ l of lx OPA reagent.
  • the reaction was incubated at room temperature for 5 minutes and then an absorbance at a wavelength of 334nm. To determine sample concentration, the reading was compared to a standard.
  • the ratio of amino nitrogen concentrations before and after total acid hydrolysis resulted in the average chain length of peptides present with each column fraction collected. See results in Table 6 for proteolytic digests of lactalbumin Methods 1 and 2.
  • Example 13 Comparative Digestion by Proteolytically Active Broth Extracts of Different Thermoactinomyces thalpophilus Strains
  • Protease containing extracts of culture broths of Thermoactinomyces thalpophilus THMl and the NCIMB bacterial strains of T. thalpophilus 9780, 11365, 11367, 11368 and 11370 were prepared using ammonium sulphate precipitation and ultrafiltration concentration. The activity of the concentrates was assayed using the azocasein method. A comparative digestion was performed using bovine lactalbumin (Sigma) and the broth extracts at an activity of 40 U/ml. A stock of 6.25% insoluble lactalbumin substrate (Sigma) was prepared in glycine buffer 0.1 M, CaCl 2 5 mM pH 10.0.
  • HMW high molecular weight; percentage values for HMW, di/tripeptides and amino acids are relative and do not include total substrate usage
  • microorganism referred to above may be made available only by the issue of a sample to an expert.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

A thermostable proteolytic enzyme which is producible by Thermoactinomyces thalpophilus THM1 (NCIMB 40778) and which: (a) has a pH optimum of about 8; (b) has a temperature optimum of about 70 °C; (c) is substantially inhibited by 1 mM phenylmethylsulphonylfluoride but substantially not inhibited by 10 mM dimethylsulphoxide, dithiothreitol or β-mercaptoethanol; (d) is at least partially dependent on the presence of calcium for its thermostability; and (e) is thermostable at 50 °C for at least 6 hours without substantial loss of activity, is useful in the preparation of protein hydrolysates for nutritional and clinical use.

Description

THERMOSTABLE PROTEOLYTIC ENZYME FROM THERMOACTTNOMYCES THALPOPHILUS THMl
This invention relates to micro-organisms capable of producing thermostable extracellular proteolytic enzymes. It also relates to the enzymes themselves, their preparation and use in the preparation of protein hydrolysates.
Proteins which have been partially digested by food-grade enzymes (i.e. protein hydrolysates) have been widely used as nutritional supplements for many years, for three main groups of patients.
The malabsorbing patient Prior hydrolysis converts the protein to a mixture of peptides and amino acids which may be better absorbed by patients with intestinal digestive disorders. It has been known for some years that the intestinal digestion products of protein are aosorbed by the intestine in two forms, that is as free amino acids and as di- and tripeptides. There are two distinct transport mechanisms involved which are shown in the Figure 1.
The cells in the centre of the picture represent the absorptive cells lining the wall of the intestine. Di- and tripeptides are absorbed intact (Craft et al . , Gut 9 425-437 (1968); Ferraris et al . , Am. J. Physiol . 257 G689-G697 (1989) ; Nicholson eϋ al . , Clin . Sci . Mol . Med . 54 205-207 (1978); Nicholson et al . , Eur. J. Clin . Inves t . 9 349-354 (1979) ; Silk Gut 15 494-501 (1974) ; and Silk eϋ al . , Br. J. Nutr. 33 95-100 (1979)) and will be hydrolysed by cellular peptidases to release free amino acids which will be transported into the blood. Longer peptides must be further hydrolysed (Adibi & Morse, J. Clin . Inves t . 60:1008-1016 (1977)) to di- and tripeptides which can then be absorbed. Amino acids have their own transporter proteins (Adibi & Morse, loc . ci t . Ganapathy & Leibach J. Biol . Chem. 258 14189-14192
(1983); Ganapathy & Leibach Curr. Opin. Cell Biol . 3 695-701 (1991) ; Gardner et al . , J. Physiol . 439 411-422
(1991) ; Kramer et al . , Biochi . Biophys . Acta 1030 41-49
(1990) ; and Kramer et al . , Eur. J. Biochem. 204 923-930 (1992) ) . It can therefore be seen that the best absorbed protein hydrolysate for use in malabsorbing patients is one based on di- and tripeptides (Friedrich et al . , Nahrung 29 167-78 (1985) ; Noack et al . , Nahrung 29 49-57
(1985) ; Proll et al . , Nahrung 29 59-67 (1985); Ganapathy & Leibach Am.J". Physiol . 249 G153-G160 (1985)) .
The allergic patient Predigestion of proteins also reduces the allergic potential of the protein, and is thus of benefit to infants with hypersensitivity to milk proteins. Since the allergic potential of a hydrolysate decreases as the size of its constituent peptides also decreases, this type of di- and tripeptide-based protein hydrolysate can be applied to these patients.
The post-operative patient By converting a large protein to smaller peptides, prior digestion markedly increases solubility. This is a useful property when trying to administer energy- and protein-dense liquid feeds to patients, with the added benefit that it allows acid flavourings (e.g. citrus which would otherwise curdle whole protein) to be added to these energy-dense food supplements, which has been shown to reduce the characteristic 'taste-fatigue' experienced by cancer patients towards milky supplements with sweet flavours. There is another important application of protein hydrolysates, which is as a source of amino acids for intravenous nutrition (Total Parenteral Nutrition - TPN) . Formulation shortcomings of some crystalline L-amino acid solutions (e.g. cysteine and tyrosine have poor solubility, whilst glutamine has poor stability) , have led to considerable effort being put into soluble and stable synthetic dipeptides containing these problem amino acids. A simpler approach would be to use protein hydrolysates containing di- and tripeptides as a much cheaper alternative to synthetic peptides, and even to free L-amino acids.
Dipeptides have half the osmolarity of the same solution weight of free amino acids. They are therefore less irritating to veins if infused intravenously. At present, intravenous nutrition solutions consist of a mixture of amino acids and glucose in a fat emulsion, together with minerals and vitamins. These solutions are hypertonic and are too irritant to infuse into a peripheral vein. They are therefore infused through a catheter which is surgically implanted under the collar bone and into a large central vein, enabling the high blood flow to dilute the solution (Peripheral Parenteral Nutrition -- PPN) . This technique has its risks and clinicians prefer infusing nutrient solutions into peripheral (e.g. arm) veins. This is a safer technique, even though it requires nutrient mixtures which are rather more dilute and therefore nutritionally inadequate. The use of complete mixtures of di- and tripeptides (from hydrolysates) would allow a more complete nutrient composition to be infused in this way. In order to prepare protein hydrolysates, which as shown above are a clinically useful means of providing protein, it is in practice necessary to use an appropriate protease.
Proteases are one of the half-dozen major industrial and food enzymes. The proteases used for food use are fungal
(e.g. Aspergillus proteases in condiment preparation and
Λucor proteases in cheese-making), plant (e.g. papain), mammalian { e . g. pancreatic proteases) and to a lesser extent bacterial (e.g. Bacillus proteases) . The constraints on use of any of these may be either legislative (i.e. a "safe" source is necessary) or functional (i.e. the stability, activity and specificity of the enzyme are important in generating the correct product) .
Current manufacturing techniques for protein hydrolysates have shortcomings, particularly the use of slaughterhouse derived (i.e. pancreatic) or plant derived enzymes which tend to produce hydrolysates with a wide range of peptide chain-lengths . This is clearly demonstrated in the tabulated summary of hydrolysates which are currently used in liquid foods for ' alabsorbing' patients (Table 1) .
Table 2 . Peptide chain-length profiles of Protein Hydrosylates used in Enteral Diets
Peptide chain-length profile (%)
Higher MW Di- & Tri¬ L- amino acids
Hydrolysate (Source) content peptide content content
SURVIMED (Fresenius) 72 10 18
TRAVASORB (Clintech) 60 20 20
AMJRJGE (Nutricia) 59 26 15
PEPTI-2000 (Nutricia) S6 27 17
PEPTISORB (E. Merck) 44 28 28
STERALDIET (Dubenard) 46 29 25
REABILAN (Roussei) 65 33 2
1IPEPTID (Lab. Roger Bellon) 23 69 8
Peptide profiles measured by Cui 11) - SEPHADEX chromatography. [Some of these diets may no lonj |er be available or may be marketed under other names.]
Although the optimum absorptive properties for protein hydrolysates have been known for some time, only one hydrolysate in Table 1 (TIPEPTID) conforms to this. The technological issue is therefore not what the final product should be, but how this may be produced most economically.
As a class, proteases and peptidases exhibit a wide-range of activities, especially in their ability to cleave at specific amino acid residues in the native protein. This gives the possibility of predicting the peptide products of protein hydrolysis. Since the nature of the final end- product is known (di- and tripeptides) , this can be achieved by careful choice of enzyme (s) .
It has now been found that there exists a micro-organism which produces an enzyme which is particularly suitable for producing protein hydrolysates for, among other things, clinical use.
According to a first aspect of the invention, there is provided a strain of Thermoactinomyces thalpophiluε designated THM1.
Tήerπioactinomyces thalpophilus THM1 has been designated as strain HB 2682 in the Applicant's internal collection of strains and deposited under the terms of the Budapest Treaty at the National Collection of Industrial and Marine Bacteria Limited (NCIMB) , Auris Business Centre, 23 St Macher Drive, Aberdeen AB2 1RY, on 18 December 1995 and given accession number NCIMB 40778. The deposit was found to be viable on 18 December 1995.
T. thalpophilus is a species within the genus Thermoactinomyces , the only genus within the group Thermoactinomycetes. Thermoactinomyces spp. are gram positive bacteria which are aerobic and saprophytic chemo-organotrophs. Most members of the genus are, like T. thalpophiluε, thermophilic. Strains of T. thalpophilus have been isolated from soil, hay, cereal grain, sugar cane bagasse, cotton, grass compost, mushroom compost, peat, air conditioners and manure.
The invention encompasses T. thalpophilus THM1 and micro¬ organisms derived from it. T. thalpophilus THM1 can be used in the derivation of other strains of micro- organisms by any of the usual methods of microbiology, including mutation (prepared for example by ultra violet light or other radiation or by chemical mutagenesis) , environmental selection, classical genetic transfer or recombinant DNA techniques. The micro-organisms of the invention produce a thermostable proteolytic enzyme whose properties are singularly useful in the preparation of protein hydrolysates .
According to a second aspect of the invention, there is provided a thermostable proteolytic enzyme which is producible by Thermoactinomyces thalpophilus THMl (NCIMB 40778) .
This heat-stable "thermophilic" protease has two manor advantages to those of the current art :
d) the heat stability of the enzyme allows hydrolysis reactions to be carried out at elevated temperatures, increasing reaction rates and reducing the danger of microbial contamination; and
(ii) it shows under defined conditions a marked tripeptide specificity (i.e. it will not hydrolyse proteins to ammo acids) , an important criterion for the preparation of nutritional hydrolysates.
In particular, the enzyme may be characterised that it:
(a) has a pH optimum of about 8;
(b) has a temperature optimum of about 70°C;
(c) is substantially inhibited by ImM phenylmethyl¬ sulphonylfluoride but substantially not inhibited by lOmM dimethylsulphoxide, dithio¬ threitol or β-mercaptoethanol ;
(d) s at least partially dependent on the presence of calcium for its thermostability; and (e) is thermostable at 50°C for at least 6 hours without substantial loss of activity.
Additionally, the enzyme has been found to have a pi of above 8.
Extracellular proteases from a number of thermophilic Actinomycetes strains have been identified, purified and partially characterised. The characterisation of an alkaline protease from an alkalophilic Thermoactinomyces isolate (HS682) has been reported (Tsuchiya et al . , Biosc . Biotech . Biochem . 56(2) , 246-250 (1992)) . This enzyme shows properties broadly similar to the specific enzyme disclosed herein (inhibition by PMSF, stabilisation by calcium) but has a significantly higher pH optimum (11.5-13.0) . Furthermore, the HS682 source organism, although not identified to species level, has very different physiological characteristics to the organism claimed herein, with a pH optimum for growth of 10.3 and a maximum growth temperature of 60°C (Tsuchiya et al . , Agric . Biol . Chem. 55(12) , 3125-3127 (1992)) .
A protease purified and partially characterised from an isolate assigned the taxonomy of Thermoactinomyces thalpophilus (Odibo & Obi, MIRCEN J. 4 327-332 (1988)) showed characteristics significantly different from the enzyme specifically described herein. Whereas the specific enzyme has been identified as a calcium- stabilised serine protease, the prior reported T. thalpophilus enzyme is said to be a neutral protease inhibited by heavy metals but not by the covalent serine reagent diisopropylfluoropnosphate. A thermostable serine protease isolated from Thermoactinomyces vulgaris (Thermitase) has been studied in considerable detail (Leuchtenberger et al . , Z. Allgem. Mikrobiol . 19(1) 27-35 (1979) ; Frόmmel & Hδhne, Biochim . Biophys . Acta 670 25-31 (1981) ; Kretschmer et al . , Z. Allgem. Mikrobiol . 22 (10) 693-703 (1982) ; Behnke et al . , Z. Allgem. Mikrobiol . 22 (8) 511-519 (1982); Brόmme & Kleine Curr. Microbiol . 11, 93-100 (1984) . However, Thermitase is substantially different from the enzyme specifically described herein, both on the basis of functional properties and because of the taxonomic difference of the source organism.
It can therefore be concluded that the enzymes the subject of this application (specifically, a thermostable serine protease derived from the thermophilic Actinomycete Thermoactinomyces thalpophiluε) , are substantially and significantly different from proteases previously reported.
The invention therefore provides in a third aspect a serine protease derivable from T. thalpophilus .
An enzyme of the invention may be produced by culturing a micro-organism as described above under conditions which cause expression (and preferably secretion) of the enzyme; suitable conditions include the use of a growth medium including glutamate. The enzyme may be harvested from the culture medium.
Enzymes of the invention may be substantially pure preparations, as determined for example by iso-electric focusing, SDS-PAGE, sequencing or crystallisation, for example. Alternatively, they may be impure preparations or crude extracts, such as ammonium sulphate precipitations or partially purified fractions (eg gel filtration or chromatography fractions. The purity of the enzyme preparation will ultimately depend on its intended use.
Also included within the scope of the invention are preparations of enzyme which are modified in some way as compared to the natural enzyme. For example, the enzyme may be covalently or non-covalently immobilised onto an appropriate immobilisation matrix. Alternatively or additionally, the enzyme may be modified in its amino acid sequence (either chemically or by site-directed mutagenesis) ; but enzymes within the scope of the invention will generally be substantially (ie at least 60, 70, 80, 90, 95 or even 99%, in increasing order of preference) homologous to the prototype enzyme. Fusion proteins including an enzyme of the invention are also contemplated.
As mentioned above, the enzymes of the invention are useful in the preparation of protein hydrolysates.
According to a fourth aspect of the invention, there is provided a method of preparing a protein hydrolysate, the method comprising digesting one or more proteins with an enzyme as described above.
The digestion may be carried out substantially to completion, in which case the product will contain a high proportion of low molecular weight peptides (particularly di- and tri-peptides) or it may be terminated before completion, in which case it will contain a lower proportion of low molecular weight peptides and a higher proportion of high molecular weight peptides. Longer hydrolysis products are preferred for the production of pharmaceutical and/or nutritional products.
In any event, the product will, in relation to the starting material (s) be enriched in di- and tripeptides and virtually free of single amino acids.
A wide variety of proteins and protein mixtures are suitable for being digested by the enzymes of the invention. For the preparation of protein hydrolysates for nutritional use, milk proteins may be used, particularly lactalbumin, such as bovine lactalbumin. More or less pure bovine lactalbumin preparations may be used; other proteins useful as substrates include other milk proteins (such as caseins) and plant proteins (such as soy proteins) . Substrate proteins may be pure or impure preparations (containing, for example, lipidaceous material) and may be in a native or denatured state.
There are few critical parameters of the hydrolysis reaction. The reaction volume may be any volume which is convenient or desirable. The reaction time depends on the substrate, the temperature, other reaction conditions and the desired end point but will typically be from 30 minutes to 48 hours. The reaction temperature will typically be from 20°C to 100°C and is preferably from 45°C to 80°C. The enzyme concentration may be from 0.1 to 1000 units/ml, preferably from 5 to 50 units/ml; and the substrate concentration may be from 0.1% to 80% (w/v) , preferably from 1 to 20%.
The invention also relates to a protein hydrolysate preparable by the above method, as well as to food and/or pnarmaceutical preparations comprising such a hydrolysate. Other envisaged uses include cosmetic and diagnostic uses and the use of protein hydrolysates as agents for modifying texture or surface coating. Fields of use are within the molecular biological, medical and pharmacological research, medical diagnostics and therapy, and the pharmaceutical, biotechnological, chemical and food industries.
For example, protein hydrolysates are incorporated in many food, dietary and cosmetic preparations for the purposes of enhancing physical, organoleptic and nutritional qualities. In analytical and research processes, protein hydrolysates may be used to prepare for use microtitre plates or blotting membranes. Protein hydrolysates have potential application in medical diagnostics as targets for drug screening or in receptor ligand binding. In the chemical industries, protein hydrolysates may be used for multiple purposes including the modification of the physical properties of emulsions such as paints, incorporation in polymeric substances and coatings for modern materials.
Preferred features of eacn aspect of the invention are as for each other aspect, mutatis mutandis .
The following description relates to a particularly preferred embodiment of the invention.
A micro-organism was isolated from a dry soil sample collected from a dry bed of a thermal stream at the Taupo thermal area in New Zealand. The micro-organism grows optimally at 50-55*C and shows proteolytic activity in casein agar plates. The micro-organism was identified as a strain of Thermoactinomyces thalpophilus by morphological and physiological characterisation. The novel strain is induced to produce extracellular protease by growth in a nutrient medium containing Na-glutamate. The extracellular proteolytic activity is enriched by fractionated ammonium-sulphate precipitation. Most of the activity is found in the 50-80% (NH4)2S04 fraction. This fraction gives after dialysis and ultrafiltration an enzyme preparation of about 3000u/ml as assayed with azocasein as substrate. The enzyme is most active at a pH of 8.0 and at a temperature of 70*C. The enzyme belongs to the family of serine proteases as shown by its 98.4% inhibition by phenylmethylsulphonylfluoride (PMSF) at 1 mM.
Ethylenediaminotetraacetic acid (EDTA) does not inhibit the enzymatic activity of the novel proteolytic enzyme but destabilises the enzyme, thereby reducing its thermal stability. It may be that calcium ions are necessary to stabilise the folding of the protein for its activity at high temperatures and possibly protecting against autolysis .
The enzyme finds particular application in the hydrolysis cf the milk proteins, at alkaline pH, for the production of hydrolysates enriched in di- and tripeptides.
The invention will now be illustrated by the following examples. The examples refer to the accompanying drawings, in which:
FIGURE 1, which has already been referred to, schematically illustrates pathways of amino acid absorption in the human intestine; FIGURE 2 refers to Example 10.2 and shows the effect of pH on THMl protease;
FIGURE 3 refers to Example 10.3 and shows the temperature optimum of THMl protease;
FIGURE 4 refers to Example 10.6 and shows the effect of calcium on THMl protease; and
FIGURE 5 refers to Example 10.7 and shows the effect of temperature on the thermostability of THMl protease.
Example 1; Isolation of the micro-organism A dry soil sample from a dry bed of a thermal stream at the Taupo thermal area in New Zealand was resuspended in sterile distilled water. Approximately 50μl of the suspended sample was spread on a Nutrient Agar plate and incubated at 55*C overnight. After incubation a large white colony was picked from this plate and screened for protease production.
Example 2: Screen for extracellular proteolytic activity The isolated micro-organism from Example 1 was subsequently tested for extracellular protease activity by culturing on a casein agar plate consisting of casein 2%, tryptone 0.5%, yeast extract 0.3%, agar 15%, pH 7.2, at 55'C overnight. The isolated organism produces extracellular protease activity as shown by zones of casein denaturation and progressive clearing by proteolytic activity. Example 3 ; Characterisation of the micro-organism
A total of six related cultures from The National Collection of Industrial and Marine Bacteria (NCIMB) were obtained for comparison with Thermoactinomyces thalpophilus THMl strain. All cultured organisms were grown on CYC agar containing Czapek Dox liquid medium 33.4g/l, yeast extract 2g/l and Casamino acids 6g/l. The gross morphology and the presence of two extracellular growth metabolites, pigment and proteolytic activity,
10 were examined. Proteolytic activity was detected on Casein agar (CA) as previously described. Cultures from NCIMB were T. thalpophilus 9780, 11365, 11367, 11368, 11370, T. vulgaris 11364. See Table 2 below.
15 Table 2 : Colony morphology of THMl and NCIMB cultures
Strain Brown Protease Colony Morphology comments Substrate Activity Mycelium (Cλ)
Form Elevation Margin
THMl + circular umbonate entire fast growing on agar
9780 - circular convex entire
11.365 ^ + circular umoonate undulate
11367 circular umoonate undulate delayed sporulat on
11368 - + circular umbonate unαulate
11370 - + circular umbonate undulate
11364 - (-) filamentous flat ilamentous
THMl grows with white aerial mycelium at 50oC on CYC agar. On this agar the organism shows a slightly dark pigmented substrate mycelium and produces a white aerial mycelium in 24 hrs. THMl is able to grow on CYC agar containing tyrosine 5 mg/ml and novobiocin 25 μg/ml. Melanin was produced after 2-3 days. The ability to grow on CYC agar containing novobiocin at 50oc is characteristic of rhermσactinomycetes species and the production of melanin on CYC agar containing tyrosine is characteristic of Thermoactinomyces thalpophilus and rherπioactino-Tjyces putidus.
THMl was able to grow on CYC agar in the presence of 200 mM NaCl. On agar containing Nutrient broth No. 2 powder
(Oxoid, UK) 12.5 g/1, agar powder 20 g/1 ( strength nutrient agar) and Arbutin 1 g/1 or M Strength nutrient agar containing Esculin 1 g/1 and 0.05% Ferric Ammonium Citrate no coloration is produced indicating that THMl is Arbutin and Esculin minus. These latter characteristics and the resistance to NaCl indicate that THMl is a strain of Thermoactinomyces thalpophilus (T. Cross, 'The monosporic Actinomycetes' pp 2091-2102 in 'The Prokaryotes' ) .
Example 4; THMl Protease is Different from Thermitase at the Genomic Level
Two oligonucleotide primers were designed by reverse translation of conserved regions of serine proteases, particularly thermitase (Meloun et al . , FEBS Lett . 183 195-200 (1985)) and the Thermoactinomyces species protease published by Lee et al . , Biosci . Biotechnol . Biochem. 60 840-6 (1996) , using the codon usage bias of Thermoaciπoinycetes. The first region chosen spans amino acid positions 14 to 21 in the thermitase sequence (S ISS-PROT P04072) and 154 to 161 in the Thermoactinomyces protease sequence published by Lee et al . (EMBL U31759) , respectively. The second region covers the serine protease active site, amino acid positions 225 to 232 in the thermitase sequence and 367 to 374 in the Thermoactinomyces protease sequence published by Lee et al . , respectively. Primers having the sequences 5' -GGA CCG CAA AAA GTC CAA GCT CCC-3' (SEQ ID NO:l) and 5' -CCT GCC ACA TGC GGT GTG GCC AT-3' (SEQ ID NO:2) were synthesised. The two oligonucleotides were used for PCR amplification of a DNA fragment (predicted length of 662 bp) , using genomic DNA from the different Thalpophilus strains obtained from the National Collection of Industrial and Marine Bacteria (NCIMB) and THMl as template. As a positive control DNA from T. vulgaris, also obtained from the NCIMB collection (NCIMB 11364) was used. The genomic DNAs were isolated according to standard procedures (Sambrook et al . Molecular Cloning, 2nd ed., Cold Spring Harbor Laboratory Press (1989)) . PCR amplification of the DNA samples yielded a band of the expected size only with T. vulgaris DNA as a template. The negative result indicates that the THMl protease is different from thermitase at the genomic level .
Example 5; Preparation for Deposit at NCIMB
Strain THMl was grown in 50mL of CYC medium overnight at 50°C. The culture was concentrated 10-fold by centrifugation (5 minutes at 1000 rpm) and resuspended in CYC medium. 500μL of the suspension was added to a sterile lyophilisation tube and dried overnight under vacuum. The lyophilisation tube was sealed under vacuum and forwarded, at room temperature, to NCIMB, by whom it was received on 18 December 1995 and allocated deposit number NCIMB 40778.
Example 6: Isolation of proteolytic activity The partial enrichment of the proteolytic enzyme was performed using ammonium sulphate precipitation. A fresh culture of the microorganism was grown on a Nutrient Agar plate overnight at 50"C. A single colony was picked and inoculated into 50 mL of sterile Nutrient broth. The culture was incubated with shaking at 300rpm overnight at 50*C. To 1000 mL of protease enrichment broth containing sodium glutamate 1.5%, KH2P040.045%, tryptone 0.2%, yeast extract 0.05%, and CaCl2 0.147%, pH 7.0, 1 mL of the overnight culture was added and the culture incubated for 24 hours at 50'C with shaking at 200rpm. After incubation the culture was first sampled and lOOμl of cell free broth checked for protease activity using the azocasein protease assay at 50"C, (see Example 6) . The positive culture was centrifuged at 8000xg for 30 min to remove cells. The supernatant was retained, transferred to a 2L beaker and slowly stirred at 4'C. Under stirring (NH4)2S04 was added slowly to give 50% saturation and left for 3 hours. The broth was centrifuged at 8000xg for 30 min and both the pellet and supernatant retained. To the supernatant, (NH4)2S04 was added to 80% saturation and left overnight at 4*C with slow stirring. The liquid was centrifuged as before and the pellet retained. The second pellet was resuspended in 15 mL 0.1 M Tris buffer, lOmM CaCl2 pH 8.0. For desalting and concentration the resuspended pellet was placed in an Amicon Centricon 10 ultrafiltration unit and centrifuged at 2500xg for 45 min. The protein solution was desalted 4 times by repeated addition of buffer to 15mL and centrifugation as above with a subsequent concentration of the solution down to a total of 3mL. The proteolytic activity of the protein isolate was assayed as described in Example 10.1 using 100 μl of a 1/200 dilution of the preparation.
The total activity contained in this preparation was found to be 8985U compared to 20500 U for the culture broth, giving a yield of 43.8%. Example 7 ; Yield Improvement of THM Protease in Stimulating Broth
The improvement of yield of THMl protease was studied in broth containing ingredients reported to stimulate the expression of proteolytic enzymes.
The optimized broth (PPB) has the following composition per litre medium:
Na glutamate 15 . 0 g
Tryptone 2 . 0 g yeast extract 0 . 5 g
KH2P04 0 . 45 g
Growth conditions in this medium were optimized in 2 L flasks on a shaking platform. The optimal conditions were found as 50 °C, pH 7.0, and 48 hrs, without excessive aeration (about 125 rpm) . Optimal yields achieved after 2 days were about 3000 U/L.
Example 8: Preparative isolation of THMl protease
A 15 L fermentation of Thermoactinomyces thalpophilus THMl was performed in a fermenter of nominal volume of 16 L over 46 hours and the extracellular protease activity determined as described in Example 6.1. The fermentation conditions were as follows: 15 L PPB medium, t = 50'C, air 7.5 Lpm. pH controlled at 7.5, stirring rate 200 rpm.
The cells were harvested by filtration and the culture broth filtered over a 10 kDa ultrafiltration membrane
(Sartorius EASY FLOW ) . The filtrate was concentrated using a 3 kDa ultrafiltration membrane (Amicon YM3) in a TCF10 unit at a N2 pressure of 40 psi. The yields of protease activity at each step are shown in Table 3. TABLE 3 - Yields of Protease Activity During isolation of THMl
Figure imgf000022_0001
Example 9: Purification by Hydrophobic Interaction Chromatography
The protease was purified on Phenyl-Sepharose using a double gradient elution system.
A sample of 2 ml of THMl protease (6000 U/ml, specific activity 5.5 U/μg) was applied at a flow rate of 2 ml/min to a 20 ml Phenyl-Sepharose column, pre-equilibrated with Tris-Cl 50mM, CaCl2 20mM, pH 8.0 (buffer A) . The column was washed with 5 volumes of buffer A, and a gradient of 1-100% of buffer B (Tris'Cl 50mM, CaCl2 20mM, NaCl IM, pH 8.0) over 5 column volumes. The enzyme was eluted with a second gradient using buffer B and buffer C (Tris-Cl 50mM, CaCl2 20mM, NaCl IM, acetone 20%) . The eluate was fractionated and the fractions tested for activity as described in Example 6.1 Out of 12000 units applied to the column, a total of 7500 units were recovered. The final yield was 62.5 % of initial activity loaded. The specific activity of the activity recovered was measured as 12 U/μg protein, a 2.2-fold purification.
Example 10: Characterisation of the proteolytic enzyme.
The parameters examined of the enzyme isolated were pH and temperature optimums, thermostability, protease type by inhibition and isoelectric point.
10.1 Azocasein protease assay
All assays performed to determine proteolytic activity used azocasein as the substrate. Azocasein 0.2%, in an appropriate buffer and respective pH, was added to Eppendorf tubes in aliquots of 900μl and preincubated at the desired temperature for about 30 seconds before initiation of the reaction. A volume of 10-100μl of sample containing the proteolytic enzyme was added to the substrate and the reaction left to proceed for 10 m utes. Then 500μl of trichloroacetic acid 15% was added to terminate the reaction. The tubes were left on the bench to cool for a further 10 minutes, to allow precipitation of unhydrolysed azocasein, then centrifuged for 2 minutes. The supernatant was removed and placed nto plastic 1ml cuvettes and the absorbance read at 420nm. One unit of proteolytic activity is defined as
ΔOD 34,20 ml"1 of 1.00.
10.2 pH Optimum
The pH optimum of the enzyme preparation was examined using azocasein 0.2% as substrate dissolved in a multi-pH buffering solution consisting of 50mM Na2HP04, 50mM H3B04, 50mM CH3COOH, adjusted to the pH values of 5, 6, 7 ,8, 9 10 and 11 with 5M NaOH. Aliquots of 900μl of the buffered azocasein were preincubated at 70"C in duplicate microcentrifuge tubes. A lOOμl aliquot of 1/200 diluted concentrated THMl enzyme preparation was added to initiate each reaction. The assay then proceeded as previously described. The results are shown in Figure 2.
10.3 Temperature Optimum 900μl aliquots of azocasein 0.2%, tris 100 mM, pH 8.0 were placed in duplicate into microcentrifuge tubes and preincubated at different temperatures from 30 to 100*C. A lOOμl aliquot of 1/200 diluted of protease preparation were added and the assay continued as described above. The results are shown in Figure 3.
10.4 Inhibition of THMl Protease
The inhibition of the partially purified protease was examined using the serine protease inhibitor, phenylmethylsulphonylfluoride (PMSF) and the thiol compounds, dimethylsulphoxide (DMSO) , dithiolthreitol (DTT) and β-mercaptoethanol. A lOμl aliquot of 1/10 dilution of the THMl enzyme preparation was incubated with the desired concentration of inhibitory reagent in tris buffer 0.IM pH 8.0 to a total of lOOμl ac room temperature for 30 minutes. After incubation the azocasein assay was performed, as described before, using the lOOμl reaction volume. The change in absorbance at 420nm was determined and compared to an enzyme only control. See Table 4. Table 4. Effect of Inhibitors on THMl protease.
Figure imgf000025_0001
10.5 Molecular Mass of Protease THMl
The molecular mass of the protease of THMl was analysed on a 15% SDS-PAG. A sample containing 5μg of purified THMl protease (Example D) was incubated either in the presence of 40 mM PMSF or~Ϊ0 mM EDTA for 30 min. at room temperature. SDS-sample buffer was added and the samples boiled for 2 minutes . The samples were loaded onto the gel and electrophoresed at 25mA for 2.5 hours. Staining with Coomassie Brilliant Blue showed a single band in the sample incubated in the presence of PMSF (lane 1) and in addition a smaller degradation product in the sample incubated in the presence of EDTA. The major band shows a molecular mass of about 32 kDa as determined from comparison with marker proteins. 10.6 Effect of calcium on the thermostability of THMl protease:
In a final volume of 200μl, CaCl2 lOmM or EDTA 20mM, 20μl of THMl protease preparation and an appropriate volume of tris lOOmM pH 8.0 were added to microcentrifuge tubes. The initial activity of each was assayed using lOOμl of reaction mixture and azocasein 0.2% for substrate, as previously described, then the remaining volume was incubated at temperatures from 40 to 100*C for 30 minutes and the final activity assayed as before. The residual activity of the enzyme was determined by comparing initial and final activities and is shown in Figure 4.
10.7 Effect of temperature on the thermostability of THMl protease:
A 10 fold dilution of THMl protease preparation was prepared in Tris lOOmM pH 8.0 to final volumes of 500μl which were incubated at 50, 60, 70 and 80"C. Aliquots of lOμl were taken at the beginning of the incubation and then hourly for 6 hours. The samples were assayed using the azocasein 0.2% protease assay at 70*C method as stated in Example 10.1. The initial activity of each was determined to be 100% and the residual activity calculated. Results are shown in Figure 5.
10.8 pi:
The isoelectric point of the enzyme was determined using the Pharmacia PHASTSYSTEM Electrophoresis unit . Two
PhastGel isoelectrophoresis gels, pH 3-9, were set up according to the Pharmacia PhastSystem manual and loaded identically with lμl of protease preparation and electrophoresed according to the IEF program. After electrophoresis, one gel was stained with coomassie blue using the Pharmacia protocol and the second gel was checked for activity by incubating with 10 ml Casein 2%, Tris lOOmM pH 8.0 for 30 minutes at 50"C. The resultant activity detected on the gel incubated with casein substrate aligned with a band detected on the coomassie blue stained gel which was located in comparison to standards at a pi of above 8.
10.9: Size Estimation by Gel Filtration
A SUPE OSE 12 HR 10/30 size exclusion column was equilibrated with buffer A (50 mM Tris-Cl, pH 7.5, 100 mM KCl) . The column was calibrated with dextran blue (Sigma D4772, 1 mg/ml) and protein standards (cytochrome C, Sigma C7150, 2 mg/ml; carbonic anhydrase, Sigma C7025, 2 mg/ml; apoprotinin, Sigma A3886, 3 mg/ml; albumin, Sigma A8531, 5 mg/ml) in 200 μl buffer B (50 mM Tris-Cl, 100 mM KCl, 5% v/v glycerol) at 0.1 ml/min.
200 μl THM-1 protease (1.025 mg/ml; 3.4 U/μg) in buffer B were applied to the column and eluted with buffer A at 0.1 ml/min. Twenty 0.25 ml fractions were collected and activity determined as described. No activity was detectable in fractions 1 to 12; the total applied activity was recovered in fractions 13 - 17, indicating an apparent molecular mass of 8 kDa as determined from the elution profile of the marker proteins. The active fractions were pooled, freeze dried and the protease resuspended in 250 μl Tris'Cl, pH 6.8, yielding a protein concentration of 430 μg/ml. To further determine the molecular mass of the protease a discontinuous SDS-PAGE according to Schagger and von Jagow (Anal. Biochem. 166 368-379 (1987)) was performed with the obtained pooled fraction. 15 μl were taken up in 15 μl sample buffer, denatured by boiling for 2 min., and electrophoresed on a 16.5% acrylamide gel at 30 mA constant current. After staining in Coomassie Blue a smgle band was visible which migrated at about 32 kDa in comparison with marker proteins (Sigma MW-SDS-17S and Promega V5231) . This result is in agreement with earlier size estimations as shown in Example 10.5.
Example 11: Proteolytic digestion of Bovine Lactalbumin by THMl Protease.
Method 1
A 5% suspension of insoluble, denatured bovine lactalbumin substrate was prepared in K2HP04 0.1M, pH 10 CaCl2 5mM with penicillm-G 20μg/ml to suppress bacterial contamination. A 20ml volume of substrate was incubated with 20unιts/ml of THMl protease at 50'C with gentle shaking in a 50ml conical flask for a total of 24 hours. Aliquots of 1ml were taken at various time points. The pH of the reaction mixture was continually checked and read usted to pH 10 using IM NaOH if required.
Method 2
The digestion reaction was performed identically as stated aoove except that the pH was modified to pH 9.5. The products of the reaction were analysed as described Example 12. The results shown in Table 5.
Example 12: Analysis of Protein substrate digestions via Cu11-Sephadex column chromatography and total acid hydrolysis/OPA-MESNA assay.
12.1 Cu11-SEPHADEX chromatography
A CUI :-SEPHADEX column was prepared as follows. 80 mL of copper sulphate 0.08 M was added to 21.3g SEPHADEX fine G- 25, and left overnight at room temperature. 40 mL NaOH IM was added with vigorous stirring to initiate the formation of a copper complex with the SEPHADEX. The suspension was centrifuged, the supernatant and any copper hydroxide layer removed and a further 40ml of NaOH IM was added. The SEPHADEX complex was recentrifuged then washed twice with Na2B407 buffer 50 mM, pH 11.5 and centrifuged. The pellet was then resuspended with about 20-50mL of the borate buffer and two columns were poured, a 40cm column and a 5 cm precolumn. The columns were put in place at 4*C and equilibrated using the said borate buffer, degassed with 100% helium, with a lml/min flow rate monitored at a 280 nm wavelength. Proteolytic digestion samples of 0.5 mL were loaded and fractions were collected for further analysis. A corresponding molecular size profile was plotted from detection of elution products to which three molecular size categories were assigned. See Table 5. 12.2 Total acid hydrolysis of chromatographic fractions.
Fractions collected from Cu11-SEPHADEX chromatography were first neutralized to pH 7.0 with 5M HCl then passed through a mini-column containing 5 mL CHELEX-IOO™ resin (Sigma Chemical Co., Poole) equilibrated in borate buffer 50 mM, pH 11.5 to remove bound copper. The column was then eluted with 2 mL of the equilibration buffer. A volume of 2 mL of the collected eluant was lyophilized overnight. The resulting powder was redissolved in 1ml of water. 0.5 ml was taken as the before hydrolysis sample. 0.5 ml of 12M HCl was added to the remaining sample and incubated overnight at 110°C. 1 mL of NaOH, 5M was added to neutralize any remaining acid and the final volume brought to 2ml. Both the before and after total acid hydrolysis samples were co-assayed for amino nitrogen using the OPA-MESNA assay method detailed in Example 12.3.
12.3 OPA-MESNA assay of chromatographic fractions.
Stocks of o-phthaldialdehyde (OPA) 40mM (lOx concentration) in methanol and 2-mercaptoethanesulphonic acid (MESNA) in Na2B407 buffer lOOmM pH 10.5 (lx concentration) were prepared. An appropriate volume of sample from either the before or after total acid hydrolysis samples was added and adjusted to a final volume of 400μl with borate buffer 50mM pH 10.5. Then 200μl of MESNA was added followed by 200μl of lx OPA reagent. The reaction was incubated at room temperature for 5 minutes and then an absorbance at a wavelength of 334nm. To determine sample concentration, the reading was compared to a standard. The ratio of amino nitrogen concentrations before and after total acid hydrolysis resulted in the average chain length of peptides present with each column fraction collected. See results in Table 6 for proteolytic digests of lactalbumin Methods 1 and 2.
Table 5. Molecular weight profile of Lactalbumin digestion by THMl Protease
Method High Molecular Low molecular Amino Acids % weight weight peptides % peptides %
1 60 40 0
2 60 40 0
Table 6. Average Peptide Chain Lengths in fractions of Lactalbumin digestion by THMl protease
Fraction Numoer Method 1 Method 2
Average Peptide Average Peptide Chain Length Chain Length
1 - -
2 - -
3 7.6 8.4
4 5.8 6.1
5 3.7 3.8
6 3.3 3.2
7 2.7 2.8
8 2.4 2.5
9 2.4 2.4
10 2.3 2.4
Example 13: Comparative Digestion by Proteolytically Active Broth Extracts of Different Thermoactinomyces thalpophilus Strains
Protease containing extracts of culture broths of Thermoactinomyces thalpophilus THMl and the NCIMB bacterial strains of T. thalpophilus 9780, 11365, 11367, 11368 and 11370 were prepared using ammonium sulphate precipitation and ultrafiltration concentration. The activity of the concentrates was assayed using the azocasein method. A comparative digestion was performed using bovine lactalbumin (Sigma) and the broth extracts at an activity of 40 U/ml. A stock of 6.25% insoluble lactalbumin substrate (Sigma) was prepared in glycine buffer 0.1 M, CaCl2 5 mM pH 10.0. To 100 ml conical flasks, 20 ml of the substrate, penicillin-G 20 μg/ml, the appropriate volume of extract and glycine buffer to a total of 25ml were added and the pH adjusted to pH 10. The flasks were incubated for 11 hrs on a shaking platform at 50*C and 100 rpm. The pH was controlled and adjusted to pH 10, initially every 30 min. , than every hour. 1 ml samples were taken to determine the digestion profile on Cu11-SEPHADEX G25 column as described.
Table 7
Comparative digestion by T. thalpophilus proteases
Enzyme Time HMW Di/tripeptide Amino Substrate Source (hours) acids digested (%) (%) (%> (%)
THMl 11 82 18 0 68
9780 11 82 15 3 64
11365 11 61 26 13 86
11367 11 62 29 9 15
11368 11 61 23 16 67
11370 11 75 13 12 72
-ve control 0 0 0 0 0
-ve control 11 92 8 0 1
(Notes: HMW = high molecular weight; percentage values for HMW, di/tripeptides and amino acids are relative and do not include total substrate usage)
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: Helix Biotechnology Ltd
(B) STREET: 182 Gloucester Place
(C) CITY: London
(D) STATE: - (E) COUNTRY: United Kingdom
(F) POSTAL CODE (ZIP) : NW1 6DS
(A) NAME: Anderson, Jasen Kingsley
(B) STREET: c/o Helix Biotechnology Ltd., Darwin Building, Gower Street
(C) CITY: London
(D) STATE: -
(E) COUNTRY: United Kingdom
(F) POSTAL CODE (ZIP) : WC1E 6BT
(A) NAME: Grimble, George Kenneth
(B) STREET: c/o Helix Biotechnology Ltd.,
Darwin Building, Gower Street
(C) CITY: London (D) STATE: -
(E) COUNTRY: United Kingdom
(F) POSTAL CODE (ZIP) : WC1E 6BT
(A) NAME: Cowan, Donald Arthur (B) STREET: c/o Helix Biotechnology Ltd.,
Darwin Building, Gower Street
(C) CITY: London
(D) STATE: -
(E) COUNTRY: United Kingdom (F) POSTAL CODE (ZIP) : C1E 6BT (ii) TITLE OF INVENTION: THERMOSTABLE PROTEOLYTIC .NZYME FROM Thermoactinomyes thalpophilus THMl
ϋii) NUMBER OF SEQUENCES: 2
(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: WordPerfect 5.1 for DOS
(v) CURRENT APPLICATION DATA:
APPLICATION NUMBER: WO PCT/GB 96/
(2) INFORMATION FOR SEQ ID NO: 1 :
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
GGACCGCAAA AAGTCCAAGC TCCC 1 11 21 INFORMATION FOR SEQ ID NO: 2.
ii) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2
CCTGCCACAT GCGGTGTGGC CAT
1 11 21
-olicani s or agent's file International application No rence number AGS / P 1 9 1 58WO
INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13
A. The indications made below relate to the microorganism referred to in the descnption on page 6 , line ft _ ι
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet
Name of depositary institution
THE NATIONAL COLLECTIONS OF INDUSTRIAL AND MARINE BACTERIA LIMITED
Address ot depositary institution (including postal code and country)
23 St. Machar Drive, Aberdeen AB2 1RY, Scotland, UK
Date of deposit -Accession Number
\3 Dec embe r 1 995 NCIMB 40778
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This infoπnation is continued on an additional sheet
Where permitted by law, and in particular under EPC Rule 28(1), the microorganism referred to above may be made available only by the issue of a sample to an expert.
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)
The indications listed below will be submitted to the International Bureau later (specify the general nature oj the indications e.g . "Accession Number of Deposit ")
For receiving Office use only For International Bureau use onlv
This sheet was received with the international s sheet was received by the International Bureau application
Figure imgf000037_0001
Authorized otficer Authorized otftcer
Form PCT/RO/134 (July 1992)

Claims

1. Thermoactinomyces thalpophilus THMl (NCIMB 40778)
2. A micro-organism which is derived from Th . thalpophilus THMl (NCIMB 40778) .
3. A thermostable proteolytic enzyme which is producible by Thermoactinomyces thalpophilus THMl (NCIMB 40778) .
4. A thermostable proteolytic enzyme producible by a micro-organism of the genus Thermoactinomyces which:
(a) has a pH optimum of about 8 ;
(b) has a temperature optimum of about 70°C;
(c) is substantially inhibited by ImM phenylmethylsulphonylfluoride but substantially not inhibited by lOmM dimethylsulphoxide, dithiothreitol or β-mercaptoethanol;
(d) is at least partially dependent on the presence of calcium for its thermostability; and
(e) is thermostable at 50°C for at least 6 hours without substantial loss of activity.
S. A serine protease derivable from T. thalpophilus .
6. A process for the preparation of a thermostable proteolytic enzyme, the process culturing a micro¬ organism as claimed in claim 1 or 2 under conditions which cause expression of the enzyme.
7. A process as claimed in claim 6, wherein the micro¬ organism is cultured in the presence of glutamate.
8. A process as claimed in claim 6 or 7, wherein the enzyme is harvested from the culture medium.
9. A method of preparing a protein hydrolysate, the method comprising digesting one or more proteins with an enzyme as claimed in claim 3, 4 or 5.
10. A method as claimed in claim 9, wherein one or more milk proteins are digested.
11. A method as claimed in claim 10, wherein the milk protein is lactalbumin.
12. A protein hydrolysate preparable by a method as claimed in claim 9, 10 or 11.
13. A food preparation comprising a hydrolysate as claimed in claim 12.
14. A pharmaceutical preparation comprising hydrolysate as claimed in claim 11.
PCT/GB1996/003192 1995-12-22 1996-12-20 Thermostable proteolytic enzyme from thermoactinomyces thalpophilus thm1 WO1997023605A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU12009/97A AU1200997A (en) 1995-12-22 1996-12-20 Thermostable proteolytic enzyme from thermoactinomyces thalpophilus thm1

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9526375.2A GB9526375D0 (en) 1995-12-22 1995-12-22 Biological material
GB9526375.2 1995-12-22
GB9600521.0 1996-01-11
GBGB9600521.0A GB9600521D0 (en) 1996-01-11 1996-01-11 Biological material

Publications (1)

Publication Number Publication Date
WO1997023605A1 true WO1997023605A1 (en) 1997-07-03

Family

ID=26308379

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/003192 WO1997023605A1 (en) 1995-12-22 1996-12-20 Thermostable proteolytic enzyme from thermoactinomyces thalpophilus thm1

Country Status (2)

Country Link
AU (1) AU1200997A (en)
WO (1) WO1997023605A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998059045A1 (en) * 1997-06-20 1998-12-30 Helix Biotechnology Ltd. Preparation of protein hydrolysates
DE19829789A1 (en) * 1998-07-03 2000-01-05 Beiersdorf Ag Against acne and inflamed comedones effective preparations containing serine proteases and one or more calcium salts
WO2011000924A1 (en) 2009-07-03 2011-01-06 Abbott Products Gmbh Spray-dried amylase, pharmaceutical preparations comprising the same and use
US8802087B2 (en) 2004-03-22 2014-08-12 Abbott Products Gmbh Pharmaceutical compositions of lipase-containing products, in particular of pancreation
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US10704037B2 (en) 2005-07-29 2020-07-07 Abbott Products Gmbh Processes for the manufacture and use of pancreatin
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD262675A1 (en) * 1987-07-29 1988-12-07 Berlin Chemie Veb METHOD FOR PRODUCING PROTEIN HYDROLYSATES FOR DIAET FOODS
WO1996028558A1 (en) * 1995-03-09 1996-09-19 The Procter & Gamble Company Thermitase variants having decreased adsorption and increased hydrolysis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD262675A1 (en) * 1987-07-29 1988-12-07 Berlin Chemie Veb METHOD FOR PRODUCING PROTEIN HYDROLYSATES FOR DIAET FOODS
WO1996028558A1 (en) * 1995-03-09 1996-09-19 The Procter & Gamble Company Thermitase variants having decreased adsorption and increased hydrolysis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEE JK ET AL: "Purification and characterization of a thermostable alkaline protease from Thermoactinomyces sp. E79 and the DNA sequence of the encoding gene", BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY, vol. 60, no. 5, May 1996 (1996-05-01), TOKYO JP, pages 840 - 846, XP000670306 *
ODIBO F J C ET AL: "Production of extracellular thermostable neutral protease of Thermoactinomyces thalpophilus", DISCOVERY AND INNOVATION, 7 (1). 1995. 11-14., XP000646683 *
TSUCHIYA K ET AL: "Purification and characterization of a thermostable alkaline protease from alkalophilic Thermoactinomyces sp. HS682.", BIOSCI BIOTECHNOL BIOCHEM, FEB 1992, 56 (2) P246-50, JAPAN, XP000670147 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998059045A1 (en) * 1997-06-20 1998-12-30 Helix Biotechnology Ltd. Preparation of protein hydrolysates
DE19829789A1 (en) * 1998-07-03 2000-01-05 Beiersdorf Ag Against acne and inflamed comedones effective preparations containing serine proteases and one or more calcium salts
US8802087B2 (en) 2004-03-22 2014-08-12 Abbott Products Gmbh Pharmaceutical compositions of lipase-containing products, in particular of pancreation
US10704037B2 (en) 2005-07-29 2020-07-07 Abbott Products Gmbh Processes for the manufacture and use of pancreatin
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
WO2011000924A1 (en) 2009-07-03 2011-01-06 Abbott Products Gmbh Spray-dried amylase, pharmaceutical preparations comprising the same and use

Also Published As

Publication number Publication date
AU1200997A (en) 1997-07-17

Similar Documents

Publication Publication Date Title
JPS6216638B2 (en)
EP2368444A1 (en) Yeast extract with high glutamic acid content and producing method thereof
EP2481798B1 (en) Aspergillus non-inherited genetic variant having enhanced protease activity, and a production method for a natural flavour enhancer employing the same
WO1997023605A1 (en) Thermostable proteolytic enzyme from thermoactinomyces thalpophilus thm1
EP0468411A2 (en) A mutant of bacterium Clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase
Bayer et al. Preparation of deglycosylated egg white avidin
US6495342B2 (en) Nitrogenous composition resulting from the hydrolysis of maize gluten and a process for the preparation thereof
CN1060212C (en) Dictyostelium dipeptidylaminopeptidase
Parrado et al. Sunflower peptones: use as nitrogen source for the formulation of fermentation media
JP4401555B2 (en) A novel chymotrypsin-like protease, a method for producing the same, and a method for producing a protein degradation product containing a novel chymotrypsin-like protease.
JP2022102874A (en) Elastin peptide
JP6697226B2 (en) New peptidase
JPS6031477B2 (en) D↓-aminoacylase and its production method
JPH10210967A (en) Highly active variant and production of protein hydrolyzate using the same
JPH07274944A (en) New variant and method for producing protein hydrolysate
JP2000078971A (en) New enzyme for synthesizing oligopeptide from d- or l- aminoacid ester and microorganism producing the same
JPH03123484A (en) Enzymatic agent for production of peptide and peptide-production process
JP2898022B2 (en) Method for producing collagen degrading enzyme
JP4071876B2 (en) Novel serine protease and production method thereof
KR100566938B1 (en) Process for preparing crude peptide from amyda japonica
EP0252216B1 (en) Microbiologically produced alpha-acetylamino cinnamic acid acylase, method of its production and its use
KR20230071371A (en) Aspergillus oryzae capable of producing mycelium comprising all kinds of essential amino acids
JP2022102875A (en) Low molecular elastin peptide
JP2740524B2 (en) Amylase inhibitor N-61
JPH10327852A (en) Separation and concentration of microorganism proliferation-promotive component from shochu distillation residual liquor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97523416

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase